InterPAD - DETAILS

Enzalutamide, 915087-33-1, MDV3100, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, MDV-3100, MDV 3100, Enzalutamide (MDV3100), XTANDI, MDV3100 (Enzalutamide), UNII-93T0T9GKNU, 93T0T9GKNU, CHEBI:68534, DTXSID10912307, 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide, MDV 3100 (Enzalutamide), 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide, 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluoro-N-methylbenzamide, Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide, Enzalutamide [USAN], Enzalutamide [USAN:INN], enzalutamidum, Enzalutamida, C21H16F4N4O2S, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, Benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl-; 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide; Enzalutamide; MDV 3100; Xtandi, Xtandi (TN), ENZALUTAMIDE [MI], Enzalutamide; MDV3100, Enzalutamide (JAN/USAN), ENZALUTAMIDE [INN], ENZALUTAMIDE [JAN], MDV3100, AldrichCPR, ENZALUTAMIDE [VANDF], Enzalutamide (MDV3100)?, MLS006010067, ENZALUTAMIDE [WHO-DD], SCHEMBL189749, GTPL6812, CHEMBL1082407, ASP9785, EX-A046, L02BB04, BCPP000169, DTXCID301341329, ENZALUTAMIDE [ORANGE BOOK], HMS3654L07, HMS3672M13, HMS3744C19, NC-54, AMY10296, ASP-9785, BCP02361, BBL102957, BDBM50425732, MFCD14155804, NSC755605, NSC766085, s1250, STL556766, AKOS015851022, MDV-3100;Enzalutamide;MDV 3100, BCP9000901, CCG-264879, CS-0317, DB08899, NSC-755605, NSC-766085, SB20413, NCGC00263120-01, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide, AC-26924, AS-17047, Benzamide,4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl-, HY-70002, MDV3100, 95%, SMR004701227, FT-0670957, NS00040668, SW219288-1, A25302, D10218, AB01565849_02, EN300-20605530, SR-01000941580, J-519668, Q1996756, SR-01000941580-1, BRD-K56851771-001-01-9

No.	Title	Href
1	Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy. Toxicol Appl Pharmacol. 2023 Nov 1;478:116699. doi: 10.1016/j.taap.2023.116699.	`Click`
2	Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment. Cell Physiol Biochem. 2018;47(2):759-773. doi: 10.1159/000490028.	`Click`
3	Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway. Biochem Biophys Res Commun. 2022 Jul 12;613:53-60. doi: 10.1016/j.bbrc.2022.04.126.	`Click`

No.

Title

Href

Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy. Toxicol Appl Pharmacol. 2023 Nov 1;478:116699. doi: 10.1016/j.taap.2023.116699.

Click

Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment. Cell Physiol Biochem. 2018;47(2):759-773. doi: 10.1159/000490028.

Click

Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway. Biochem Biophys Res Commun. 2022 Jul 12;613:53-60. doi: 10.1016/j.bbrc.2022.04.126.

Click

Name	Enzalutamide
PubChem CID	15951529
Molecular Weight	464.4g/mol
Synonyms	Enzalutamide, 915087-33-1, MDV3100, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, MDV-3100, MDV 3100, Enzalutamide (MDV3100), XTANDI, MDV3100 (Enzalutamide), UNII-93T0T9GKNU, 93T0T9GKNU, CHEBI:68534, DTXSID10912307, 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide, MDV 3100 (Enzalutamide), 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide, 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluoro-N-methylbenzamide, Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide, Enzalutamide [USAN], Enzalutamide [USAN:INN], enzalutamidum, Enzalutamida, C21H16F4N4O2S, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, Benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl-; 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide; Enzalutamide; MDV 3100; Xtandi, Xtandi (TN), ENZALUTAMIDE [MI], Enzalutamide; MDV3100, Enzalutamide (JAN/USAN), ENZALUTAMIDE [INN], ENZALUTAMIDE [JAN], MDV3100, AldrichCPR, ENZALUTAMIDE [VANDF], Enzalutamide (MDV3100)?, MLS006010067, ENZALUTAMIDE [WHO-DD], SCHEMBL189749, GTPL6812, CHEMBL1082407, ASP9785, EX-A046, L02BB04, BCPP000169, DTXCID301341329, ENZALUTAMIDE [ORANGE BOOK], HMS3654L07, HMS3672M13, HMS3744C19, NC-54, AMY10296, ASP-9785, BCP02361, BBL102957, BDBM50425732, MFCD14155804, NSC755605, NSC766085, s1250, STL556766, AKOS015851022, MDV-3100;Enzalutamide;MDV 3100, BCP9000901, CCG-264879, CS-0317, DB08899, NSC-755605, NSC-766085, SB20413, NCGC00263120-01, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide, AC-26924, AS-17047, Benzamide,4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl-, HY-70002, MDV3100, 95%, SMR004701227, FT-0670957, NS00040668, SW219288-1, A25302, D10218, AB01565849_02, EN300-20605530, SR-01000941580, J-519668, Q1996756, SR-01000941580-1, BRD-K56851771-001-01-9
Drug Type	Small molecule
Formula	C₂₁H₁₆F₄N₄O₂S
SMILES	CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI	1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
InChIKey	WXCXUHSOUPDCQV-UHFFFAOYSA-N
CAS Number	915087-33-1
ChEMBL ID	CHEMBL1082407
ChEBI ID	CHEBI:68534
TTD ID	D0QK5X
Drug Bank ID	DB08899
KEGG ID	D10218
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Polyphyllin I, Enzalutamide
Partner Name	Polyphyllin I
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Gene Regulation	Down-regulation	Expression	MUC1	hsa4582
Gene Regulation	Down-regulation	Expression	RELA	hsa5970
In Vitro Model	DU145	Prostate carcinoma	Homo sapiens (Human)	CVCL_0105
In Vitro Model	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
In Vivo Model	DU145 prostate cancer cells carrying the luciferase report gene (1×10⁶ cells) in 100 µL PBS were implanted via subcutaneous injection into the flanks of the mice.
Result	Our results indicate that PPI inhibits the growth of CRPC cells by inhibiting p65 protein and concomitantly reducing HOTAIR expression, thereby suppressing MUC1 gene expression. The novel regulatory interaction of p65 and HOTAIR converge in the inhibition of MUC1 expression and overall PPI response. The combination of PPI and enzalutamide exhibits synergy. This study reveals a novel mechanism underlying the synergistic inhibitory effect of PPI and enzalutamide on the growth of CRPC cells.

Pair Name	Lycopene, Enzalutamide
Partner Name	Lycopene
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	AR	hsa367
	Down-regulation	Phosphorylation	EZH2	hsa2146
	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	PCNA	hsa5111
In Vitro Model	LNCaP C4-2B	Prostate carcinoma	Homo sapiens (Human)	CVCL_4784
In Vitro Model	22Rv1	Prostate carcinoma	Homo sapiens (Human)	CVCL_1045
In Vivo Model	22RV1 cells (2×10⁶) were injected into left tibia or the right flank of nude mice.
Result	These results suggest that the enhanced antitumor effects of enzalutamide by lycopene may be related to the reduction of AR protein levels through lycopene-mediated inhibition of AKT/EZH2 pathway, which may provide a new approach to improve the efficacy of enzalutamide in CRPC.

Pair Name	Lupeol, Enzalutamide
Partner Name	Lupeol
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Gene Regulation	Down-regulation	Expression	CFLAR	hsa8837
	Down-regulation	Expression	HNF4A	hsa3172
	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Expression	PTEN	hsa5728
In Vitro Model	PNT2	Healthy	Homo sapiens (Human)	CVCL_2164
	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
	PTEN-CaP8	Carcinoma of the mouse prostate gland	Mus musculus (Mouse)	CVCL_0F37
In Vivo Model	1×10⁶ PTEN-CaP8 cells were introduced subcutaneously in the right flanks of mice.
Result	Lupeol enhances the pharmacological efficacy of Enzalutamide and reduces the adverse effects. Thus, Lupeol could be a promising adjuvant for improving Enzalutamide-based treatment outcomes and warrant further research.